There is no single “best” cream for skin cancer. The two most effective and widely used options are fluorouracil (5-FU) and imiquimod, both approved for treating superficial skin cancers and precancerous growths called actinic keratoses. Which one works best for you depends on the type, size, and location of your lesion, and your dermatologist will typically choose between them based on those factors.
Topical creams are only appropriate for certain types of skin cancer. They work for superficial basal cell carcinoma and precancerous actinic keratoses. They are not used for melanoma, deeper basal cell carcinomas, or most squamous cell carcinomas. If your skin cancer extends below the surface layer of skin, surgery is the standard treatment.
Fluorouracil (5-FU): The Most Widely Used Option
Fluorouracil, sold under the brand name Efudex, is a topical chemotherapy cream that kills abnormal skin cells by disrupting their ability to replicate DNA. It’s been the workhorse of topical skin cancer treatment for decades. The FDA approved it specifically for superficial basal cell carcinomas in patients where surgery isn’t practical, such as people with multiple lesions or lesions in hard-to-treat locations.
For precancerous actinic keratoses, 5-FU delivers strong results. In a study of 150 patients with over 400 lesions, 92% achieved complete clearance after treatment with 4% 5-FU cream. The standard course involves applying the cream twice daily for about four weeks for superficial basal cell carcinoma, though your dermatologist may adjust this timeline.
For superficial basal cell carcinoma specifically, a large randomized trial comparing all three major non-surgical options found that 80.1% of patients treated with fluorouracil cream were tumor-free at one year.
Imiquimod: The Immune-Boosting Alternative
Imiquimod (brand name Aldara) works differently from fluorouracil. Rather than directly killing cancer cells, it stimulates your immune system to attack them. It’s applied once daily, typically five days a week for six weeks when treating superficial basal cell carcinoma.
In head-to-head trials, imiquimod slightly outperforms fluorouracil for superficial basal cell carcinoma. That same large randomized trial found 83.4% of imiquimod patients were tumor-free at one year, compared to 80.1% for fluorouracil. The difference between the two creams wasn’t statistically significant, meaning both are considered effective options.
At three years, a separate trial found that 84% of patients treated with imiquimod for superficial basal cell carcinoma were still successfully treated. That’s a strong result for a cream, though it falls short of surgery’s 98% success rate in the same study.
How Creams Compare to Surgery
Topical creams are a genuine treatment option, but they don’t match surgery’s long-term track record. Five-year recurrence rates tell the story clearly: standard surgical excision has a recurrence rate of about 5.2%, and Mohs surgery (a precision technique) comes in at 3.2%. Imiquimod’s five-year recurrence rate is 17.5%, roughly seven times higher than surgical excision in the same study group.
This doesn’t mean creams are a poor choice. They’re appropriate when surgery is impractical, when you have multiple lesions across a wide area, or when tumors sit in locations that would heal poorly after cutting. They’re also used for patients who can’t tolerate surgery due to age or other health conditions. But if you have a single, accessible superficial basal cell carcinoma, most guidelines favor surgery as the more definitive option.
Creams also have an important limitation: because they only penetrate the surface layers of skin, any cancer cells deeper in the dermis can survive undetected. This can create a false impression that the cancer is gone when it isn’t, which is one reason follow-up monitoring matters.
Other Topical Options
Two additional topical treatments are worth knowing about, though they’re used for precancerous actinic keratoses rather than confirmed skin cancers.
Diclofenac sodium 3% gel (Solaraze) is a gentler option that works through anti-inflammatory pathways. It requires a much longer treatment course, typically 90 days of twice-daily application, and achieves complete clearance in about 50 to 58% of patients. That’s a lower success rate than fluorouracil or imiquimod, but the tradeoff is significantly milder skin reactions. It’s often chosen for patients who can’t tolerate the more aggressive creams.
Tirbanibulin (Klisyri) is the newest approved option for actinic keratoses. Its main advantage is convenience: the entire treatment course is just five days of once-daily application. It’s designed for treating patches of sun-damaged skin on the face or scalp.
What Treatment Feels Like
If you’re prescribed fluorouracil or imiquimod, the treatment process is intentionally uncomfortable, and that’s actually a sign it’s working. The cream targets damaged and abnormal cells, causing them to become inflamed and die off.
With fluorouracil, your skin typically becomes red and irritated after one to two weeks of use. This progresses to peeling, crusting, and sometimes erosion of the treated area. These reactions can persist for several weeks after you stop applying the cream. The treated area essentially looks and feels like a raw, sunburned wound before it heals. Imiquimod causes similar reactions, with redness, swelling, crusting, and itching. Both creams can occasionally lead to local wound infections that need additional care.
The intensity of these reactions catches many people off guard. It helps to know in advance that looking worse is part of getting better. Your dermatologist can adjust the application schedule if side effects become too severe. In clinical trials of imiquimod, patients who couldn’t tolerate daily application were advised to take a week-long break and restart at five days per week.
Which Tumors Qualify for Cream Treatment
Not every skin cancer can be treated with a cream. The key factors that determine eligibility are tumor type, size, depth, and location.
Creams work for superficial basal cell carcinomas, meaning tumors confined to the outermost layer of skin. Most clinical experience with imiquimod is limited to tumors smaller than 2 square centimeters that aren’t in high-risk areas. High-risk locations include anywhere within about a centimeter of the hairline, eyes, nose, mouth, or ears, as well as the genital area, hands, and feet. Tumors in these zones are generally treated with surgery because recurrence carries greater consequences.
If you have a nodular basal cell carcinoma (one that grows deeper into the skin), a squamous cell carcinoma with invasion, or any form of melanoma, topical creams are not appropriate. These cancers require surgery, and sometimes additional treatments like radiation.